Although the protective effect of IL-17RA inhibition on asthma was relatively minor in the sex-combined trial (ClinicalTrials.gov: NCT01902290), our study suggested that the efficacy of this target on asthma in males may be worth reconsideration in future trials. This evidence concerns the gene IL17RA and asthma.